Overview: Kynurenic Acid TestIntroduction: The Kynurenic Acid Test tests for kynurenic acid to assess metabolic or neurological disorders, helping diagnose conditions causing cognitive issues or fatigue. Affecting 1 in 10,000 people with neurological disorders, kynurenic acid imbalance poses diagnostic challenges due to subtle symptoms. Following 2023 American Academy of Neurology (AAN) guidelines, it uses LC-MS/MS for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: Kynurenic Acid Level Test, Neuro-Metabolic Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Kynurenic acid testing began in the 1980s with research by Schwarcz, who linked it to neurological disorders. LC-MS/MS advancements in the 2000s by Agilent improved detection, surpassing earlier HPLC methods.
Purpose: Measures kynurenic acid levels to diagnose metabolic or neurological disorders, guides therapy or monitoring, and evaluates patients with cognitive issues, aiming to manage symptoms.
Test Parameters: Kynurenic acid levels
Pretest Condition: No special preparation required. Collect urine, plasma, or CSF. Report history of neurological or metabolic issues.
Specimen: Urine (sterile container, 5-20 mL), Plasma (NaHep, 2-4 mL), CSF (sterile container, 1-2 mL); 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cognitive issues or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neurodegeneration), and sample collection risks.
Procedural Considerations: Uses LC-MS/MS to measure kynurenic acid, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest disorder, guiding therapy. Early intervention might prevent progression, while untreated cases lead to worsening. Normal levels may require other metabolite tests.
Specialist Consultation: Consult a neurologist or metabolic specialist for interpretation.
Additional Supporting Tests: Tryptophan levels, MRI, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. False negatives possible with early disease.
References: AAN Guidelines, 2023; Journal of Neurochemistry, Schwarcz R, 2022.
